Conheça a DECH, Doença do Enxerto contra o Hospedeiro, uma condição multissistêmica, pós transplante alogênico de medula óssea/células tronco hematopoiéticas, que pode se manifestar meses ou mesmo anos pós transplante.1

Nesta página você encontrará:

  Acesso a materiais exclusivos

  Vídeo-aula com especialistas

    Informações para seu paciente

Para continuar lendo confirme que você é um profissional da saúde.
CLIQUE AQUI PARA SE CADASTRAR
Já possui uma conta? Clique aqui.

Compartilhar

    Referências

    1. Grube M, Holler E, Weber D, Holler B, Herr W, Wolff D.
      Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation-results from a single-center observational study.
      Biol Blood Marrow Transplant. 2016;22(10):1781-1791. doi:10.1016/j.bbmt.2016.06.020

    2. Arai S, Arora M, Wang T, et al; Graft-vs-Host Disease Working Committee of the CIBMTR.
      Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
      Biol Blood Marrow Transplant. 2015;21(2):266-274. doi:10.1016/j.bbmt.2014.10.021

    3. Fiuza-Luces C, Simpson RJ, Ramírez M, Lucia A, Berger NA.
      Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients.
      one Marrow Transplant. 2016;51(1):13-26. doi:10.1038/bmt.2015.195

    4. Martires KJ, Baird K, Steinberg SM, et al.
      Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease.
      Blood. 2011;118(15):4250-4257. doi:10.1182/blood-2011-04-350249

    5. Hamilton BK.
      Updates in chronic graft-versus-host disease.
      Hematology Am Soc Hematol Educ Program. 2021;2021(1):648-654. doi:10.1182/hematology.2021000301

    6. Kitko CL, White ES, Baird K.
      Fibrotic and sclerotic manifestations of chronic graft-versus-host disease.
      Biol Blood Marrow Transplant. 2012;18(1 suppl):S46-S52. doi:10.1016/j.bbmt.2011.10.021

    7. Lee SJ, Nguyen TD, Onstad L, et al.
      Success of immunosuppressive treatments in patients with chronic graft-versus-host disease.
      Biol Blood Marrow Transplant. 2018;24(3):555-562. doi:10.1016/j.bbmt.2017.10.042

    8. Jiwani S.
      Real-world QOL survey for patients with acute and chronic GvHD post allo-SCT in 5 European countries.
      GvHDHub. Updated May 24, 2021. Accessed July 8, 2024. https://gvhdhub.com/medical-
      information/real-world-qol-survey-for-patients-with-acute-and-chronic-gvhd-post-allo-sct-in-5-european-countries

    9. Grube M, Holler E, Weber D, Holler B, Herr W, Wolff D.
      Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation-results from a single-center observational study.
      Biol Blood Marrow Transplant. 2016;22(10):1781-1791. doi:10.1016/j.bbmt.2016.06.020

    10. Arai S, Arora M, Wang T, et al; Graft-vs-Host Disease Working Committee of the CIBMTR.
      Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
      Biol Blood Marrow Transplant. 2015;21(2):266-274. doi:10.1016/j.bbmt.2014.10.021

    11. JagasiaMH,GreinixH i ,AroraM ,e tal.
      NationalInstitutesofHealthconsensusdevelopmentprojecto ncriteriafordinicaltrialsi nchronic graft-versus-hostdiseuse:1.The2014DiagnosisandSlaging WoGrokupinRgepoBriotl.
      BolodMarowTransplane,201521(3):389-401.et. GO:10.1016/1000k4018.1200

    12. Toubai T, Magenau J.
      Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease.
      Blood. 2020;136(4):429-440. doi:10.1182/blood.2019000953